Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia

Abstract

We compared the outcomes of salvage chemotherapy in 146 patients with relapsed (57.5%) or refractory (42.5%) AML who received CLAG-M (51%), MEC (39%) or CLAG (10%). Minimal residual disease (MRD) was assessed by flow cytometry. Bivariate, Kaplan–Meier, and Cox regression analyses were conducted. Complete remission (CR) rate of 46% (CLAG-M 54% versus MEC/CLAG 40%, p = .045) was observed with MRD-negative CR of 33% (CLAG-M 39% versus MEC/CLAG 22%, p = .042). Median overall survival (OS) was 9.7 months; the longest OS occurred with CLAG-M (13.3, 95%CI 2.4–24.3) versus MEC (6.9, 95%CI 2.9–10.9) or CLAG (6.2, 95%CI 2.4–12.6) (p = .025). When adjusted for age, gender, relapsed/refractory AML, poor risk AML, MRD, chemotherapy and transplant, CLAG-M (HR 0.63, 95% CI 0.40–0.98, p = .042), MRD-negativity (HR 0.15, 95% CI 0.07–0.30, p < .001) and transplant (HR 0.22, 95% CI 0.13–0.39, p < .001) were associated with higher OS. Our findings confirm that CLAG-M is a reasonable salvage regimen for RR-AML followed by transplant.

Keywords:

• Acute myeloid leukemia
• salvage chemotherapy
• relapsed/refractory leukemia
• hematopoietic stem cell transplant
• minimal residual disease

Disclosure statement

The authors report no conflict of interest. Ehab Atallah has a financial relationship (consultancy) with Novartis, BMS, Jazz, Abbvie, and Pfizer.

Additional information

Funding

This work was supported by the University of Wisconsin Carbone Cancer Center Support Grant P30 CA014520.